Seaport Therapeutics goes public as obesity drug race heats up and FDA commissioner faces White House scrutiny
Seaport Therapeutics announced a successful initial public offering, with CEO Daphne Zohar discussing the company’s next steps on the latest Readout LOUD podcast.
The episode also highlighted the escalating competition in the obesity market, noting the ongoing battle between Eli Lilly and Novo Nordisk over their respective weight‑loss pills.
Cytokinetics reported a positive outcome from a Phase 3 trial, adding another noteworthy development to the week’s biotech news.
Finally, the hosts touched on FDA Commissioner Marty Makary’s recent difficulties with the White House, rounding out a busy news roundup for the sector.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles”
read at STAT ↗
comments(0)
5-min edit window · permanent after that